Senti Biosciences Overview
Latest ROE for Senti Biosciences: 1457.34% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow1457.34%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SNTI is 1457.34%. That is above the sector sector average of 11.64%. Investors often review this figure alongside Senti Biosciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SNTI currently prints 1457.34% for ROE, while the sector average sits near 11.64%. That is roughly 12423.7% above the sector mean. Large gaps often invite a closer look at Senti Biosciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Senti Biosciences converts resources into returns. At 1457.34%, SNTI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SNTI's ROE (1457.34%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
